

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A method of identifying a candidate RAC, axin, and beta-catenin pathways modulating agent, said method comprising the steps of:

(a) providing an assay system comprising a Mitogen Activated Protein Kinase (MAPK) polypeptide comprising SEQ ID NO: 36, 37, 38 and 40 or nucleic acid comprising SEQ ID NO: 1, 10, 12, 13, 21, and 29, wherein the assay system is capable of detecting the activity or expression of MAPK;

(b) contacting the assay system with a test agent that modulates the activity or expression of MAPK ~~under conditions whereby, but for the presence of the test agent, the system provides a reference activity;~~ and

(c) determining the activity or expression of the MAPK polypeptide or nucleic acid in the assay system in the presence or absence of the test agent of step (b), wherein a change in MAPK activity or expression between the presence and absence of the test agent ~~detecting a test agent biased activity of the assay system, wherein a difference between the test agent-biased activity and the reference activity identifies the test agent as a candidate RAC, axin, and beta-catenin pathways modulating agent.~~

2. (Original) The method of Claim 1 wherein the assay system comprises cultured cells that express the MAPK polypeptide.

3. (Currently amended) The method of Claim 2 wherein the cultured cells additionally have defective RAC, axin, and beta-catenin pathway function.

4. (Original) The method of Claim 1 wherein the assay system includes a screening assay comprising a MAPK polypeptide, and the candidate test agent is a small molecule modulator.

5. (Currently amended) The method of Claim 4 wherein the screening assay is a kinase assay.

6. (Original) The method of Claim 1 wherein the assay system is selected from the group consisting of an apoptosis assay system, a cell proliferation assay system, an angiogenesis assay system, and a hypoxic induction assay system.

7. (Original) The method of Claim 1 wherein the assay system includes a binding assay comprising a MAPK polypeptide and the candidate test agent is an antibody.

8. (Original) The method of Claim 1 wherein the assay system includes an expression assay comprising a MAPK nucleic acid and the candidate test agent is a nucleic acid modulator.

9. (Original) The method of claim 8 wherein the nucleic acid modulator is an antisense oligomer.

10. (Currently amended) The method of Claim 8 wherein the nucleic acid modulator is a phosphothioate morpholino oligomer (PMO).

11. (Currently amended) The method of Claim 1 additionally comprising:

(d) administering the candidate Rac, axin, and beta-catenin pathways modulating agent identified in (c) to a model system comprising cells defective in Rac, axin, and beta-catenin pathways function and[[,]] detecting a phenotypic change in the model system that indicates that the Rac, axin, and beta-catenin pathways function is restored when compared relative to wild-type cells.

12. (Currently amended) The method of Claim 11 wherein the model system is a mouse model with defective Rac, axin, and beta-catenin pathways function.

13. (Currently amended) A method for modulating a Rac, axin, and beta-catenin pathways of a cell comprising contacting a cell defective in Rac, axin, and beta-

catenin pathways function with a candidate modulator that specifically binds to a MAPK polypeptide, whereby Rac, axin, and beta-catenin pathways function is restored.

14. (Currently amended) The method of claim 13, wherein the candidate modulator is administered to a vertebrate animal predetermined to have a disease or disorder resulting from a defect in Rac, axin, and beta-catenin pathways function.

15. (Original) The method of Claim 13 wherein the candidate modulator is selected from the group consisting of an antibody and a small molecule.

16. (Currently amended) The method of Claim 1, comprising the additional steps of:

(d) providing a ~~secondary~~ second assay system comprising cultured cells or a non-human animal expressing MAPK and capable of detecting change in the RAC, axin, and beta-catenin pathways,

(e) contacting the ~~secondary~~ second assay system with the test agent of (b) ~~or an agent derived therefrom under conditions whereby, but for the presence of the test agent or agent derived therefrom, the system provides a reference activity;~~ and

(f) ~~detecting an agent-biased activity of the second assay system, wherein a difference between the agent-biased activity and the reference activity of the second assay system measuring the Rac, axin, and beta-catenin pathways in the presence or absence of the test agent, wherein the detection of a difference in the presence and absence of the test agent confirms the test agent or agent derived therefrom as a candidate RAC, axin, and beta-catenin pathways modulating agent; and wherein the second assay detects an agent-biased change in the RAC, axin, and beta-catenin pathways.~~

17. (Original) The method of Claim 16 wherein the secondary assay system comprises cultured cells.

18. (Original) The method of Claim 16 wherein the secondary assay system comprises a non-human animal.

19. (Original) The method of Claim 18 wherein the non-human animal mis-expresses a Rac, axin, and beta-catenin pathways gene.
20. (Original) A method of modulating Rac, axin, and beta-catenin pathways in a mammalian cell comprising contacting the cell with an agent that specifically binds a MAPK polypeptide or nucleic acid.
21. (Original) The method of Claim 20 wherein the agent is administered to a mammalian animal predetermined to have a pathology associated with the Rac, axin, and beta-catenin pathways.
22. (Original) The method of Claim 20 wherein the agent is a small molecule modulator, a nucleic acid modulator, or an antibody.
23. (Withdrawn) A method for diagnosing a disease in a patient comprising:
- (a) obtaining a biological sample from the patient;
 - (b) contacting the sample with a probe for MAPK expression;
 - (c) comparing results from step (b) with a control;
 - (d) determining whether step (c) indicates a likelihood of disease.
24. (Withdrawn) The method of claim 23 wherein said disease is cancer.
25. (Withdrawn) The method according to claim 24, wherein said cancer is a cancer as shown in Table 1 as having >25% expression level.